Strategic Partnerships SFJ specializes in financing, clinical development, and regulatory resources for drug development, presenting a potential sales entry point for CROs, biotech partners, and pharma companies seeking non-dilutive funding and accelerated development timelines.

Global footprint With offices across the US, Europe, Japan, Singapore, Cayman, and Korea, SFJ offers multinational development capabilities that can complement partners aiming for global regulatory submissions and international market access.

Recent exits SFJ has experience divesting or licensing assets and transferring US rights (example: bentracimab) which signals readiness for partnerships involving asset monetization, rights deals, or strategic exits—a potential avenue for clients seeking licensing or divestiture options.

Clinical development strength A track record of leading clinical development and regulatory approval activities for diverse partners (Merck, PhaseBio, Nektar, Apellis, etc.) indicates SFJ can be a knowledgeable co-development partner to accelerate programs across stages and therapeutic areas.

Financial backing With substantial funding and a revenue range in the mid-market, SFJ can support early to mid-stage programs that require non-dilutive capital, making them a compelling partner for companies seeking financing alongside development expertise.